A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.
Chasing CAR-T, biotech finds its next gold rush in autoimmune disease
Biotech investors have been buzzing around new areas of drug development this year, such as the red-hot obesity market. But there’s one field that has